Navigation Links
CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
Date:9/6/2011

KING OF PRUSSIA, Pa., Sept. 6, 2011 /PRNewswire/ -- To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it is seeking proposals for the next round of Interlaken Leadership Awards.  Established in 2010, this annual global awards program provides monetary grants and/or product supply to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurological disorders.

From the management of primary immunodeficiency to the control of autoimmune and inflammatory conditions, Ig therapy has a wide range of indications. The Interlaken Leadership Awards program was created to help identify new clinical applications for polyvalent immunoglobulins for potential further clinical investigation, with the ultimate goal of having a positive impact on the quality of life for people who are diagnosed with a wide range of neurological conditions, for example, multifocal motor neuropathy, myasthenia gravis, and chronic pain.

"The number of potential clinical applications for immunoglobulin therapy continues to expand and recent research has identified several novel and promising uses that may be able to help people with debilitating and degenerative neurological conditions," said Jeffrey Baggish, M.D., Director of Medical Affairs, Immunology & Pulmonary at CSL Behring. "The Interlaken Leadership Awards further underpins CSL Behring's position at the forefront of immunoglobulin research by supporting investigators who are devoted to improving patient outcomes by advancing the evolving science behind Ig therapy."

Proposal Submission Process

Any individual actively engaged in clinical or basic research in a field of study consistent with the goals of the Interlaken Leadership Awards program is eligible.  

For more information, please visit: www.InterlakenLeadershipAwards.com.  

About the International Immunoglobulin Symposium in Interlaken

For more than three decades, CSL Behring has sponsored a high-level scientific symposium in Interlaken, Switzerland. First held in 1981, and most recently in 2009, the International Immunoglobulin Symposium focuses exclusively on scientific and clinical research in the field of polyvalent immunoglobulins.

Research presented at the Interlaken symposium is consistently at the forefront of immunoglobulin research. Since its inception, the International Immunoglobulin Symposium has won the respect and support of top international scientists and clinicians from many different fields of research. For more information, please visit: http://www.interlakenleadershipawards.com/symposium.aspx.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.

Contact:
Greg Healy, Senior Manager, Communications & Public Relations
Commercial Operations
CSL Behring
610-878-4841
Greg.Healy@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
2. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
3. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
4. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
5. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
6. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
7. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
8. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
9. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
10. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
11. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):